tradingkey.logo

Illumina Inc

ILMN
查看详细走势图
119.720USD
-13.890-10.40%
收盘 02/06, 16:00美东报价延迟15分钟
18.32B总市值
21.83市盈率 TTM

Illumina Inc

119.720
-13.890-10.40%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-10.40%

5天

-17.33%

1月

-18.62%

6月

+26.78%

今年开始到现在

-8.72%

1年

-2.51%

查看详细走势图

TradingKey Illumina Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Illumina Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名43/205位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价136.64。中期看,股价处于平稳状态。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Illumina Inc评分

相关信息

行业排名
43 / 205
全市场排名
133 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Illumina Inc亮点

亮点风险
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
业绩转盈
公司业绩转盈,最新年度盈利美元
估值高估
公司最新PE估值21.83,处于3年历史高位
机构减仓
最新机构持股161.13M股,环比减少11.60%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值4.98K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.31

分析师目标

根据 20 位分析师
持有
评级
136.636
目标均价
+2.26%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Illumina Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Illumina Inc简介

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
公司代码ILMN
公司Illumina Inc
CEOThaysen (Jacob)
网址https://www.illumina.com
KeyAI